Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for renal cell carcinoma. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Optimizing Front-Line Decision-Making for Advanced Renal Cell Carcinoma (RCC)

MODULE 2: Sequencing of Therapy for Patients with Relapsed/Refractory RCC; Novel Approaches Under Investigation

MODULE 3: Practical Considerations with the Use of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced RCC

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).

Learning Objectives

• Effectively apply research findings and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic RCC (mRCC).
• Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for mRCC, and develop strategies to appropriately integrate this approach into patient care.
• Appraise available clinical trial data evaluating approved and investigational anti-PD-1/ PD-L1 antibody/multikinase inhibitor combinations for previously untreated mRCC, and counsel patients about the risks and benefits of these novel regimens.
• Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC that progresses on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other formulations.
• Recognize side effects and toxicities commonly associated with approved and investigational therapeutic approaches, and use this information to develop supportive care plans for patients with RCC receiving these agents and regimens.
• Recall available and emerging data with other investigational agents and strategies currently in testing for RCC, and where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Hutson has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Agarwal — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc. Dr Choueiri — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Eli Lilly, EMD Serono Inc, Exelixis Inc, Merck, Novartis, Pfizer Inc; Contracted Research: Exelixis Inc, GlaxoSmithKline. Dr Hammers — Advisory Committee: ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Exelixis Inc, Merck, Novartis, Pfizer Inc, Surface Oncology; Contracted Research: Bristol-Myers Squibb Company, Merck. Dr Jonasch — Consulting Agreements: Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, Merck, Novartis, Pfizer Inc; Contracted Research: Merck, Telix Pharmaceuticals Ltd; Data and Safety Monitoring Board/Committee: Pfizer Inc. Dr McDermott — Consulting Agreements: Alkermes, Bristol-Myers Squibb Company, Calithera Biosciences, Eisai Inc, Eli Lilly & Company, EMD Serono Inc, Iovance Biotherapeutics, Inc, Merck, Pfizer Inc, Werewolf Therapeutics; Contracted Research: Alkermes, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Pfizer Inc, X4 Pharmaceuticals, Inc. Dr Motzer — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Pfizer Inc. Dr Oh — Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Conjupro Bio-Pharmaceuticals, Curio Biotech SA, The Foundry, LLC, Janssen Biotech Inc, Merck, Sanofi Genzyme, TeneoBio. Dr Plimack — Advisory Committee: Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc, Pfizer Inc. Prof Powles — Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme Corp, Pfizer Inc, Roche Laboratories Inc. Dr Rini — Advisory Committee and Consulting Agreements: 3D Medicines Corporation, Alkermes, Aravive Inc, Arrowhead Pharmaceuticals, Inc, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Compugen Ltd, Corvus Pharmaceuticals, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Pfizer Inc, Shionogi Inc, Surface Oncology, Synthorx; Contracted Research: Aravive Inc, Arrowhead Pharmaceuticals, Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dragonfly Therapeutics, Exelixis Inc, F Hoffmann-La Roche Ltd, Immunomedics Inc, Incyte Corporation, Merck, Mirati Therapeutics, Pfizer Inc, Seagen Inc, Surface Oncology, Taris Biomedical.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc and Exelixis Inc.